Skip to main content
S&P 5007,670.12+1.03%DOW52,648.30+1.12%NASDAQ26,375.87+1.13%BTC$77,135.00+0.09%ETH$2,547.11+3.61%GOLD$4,400.80-0.15%OIL$99.70-2.71%
Smart Investors Daily
BB

NASDAQ · BBOT

BridgeBio Oncology Therapeutics Inc.

Healthcare · Biotechnology

$5.52

Down-$0.50 (-9.06%)

Updated Sep 11, 2026, 4:34 PM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.03B
P/E ratio
-2.62
Dividend yield
0.00%
52-week range
$5.48 – $14.87
Volume
2.79M
Avg. volume
237.22K

Price performance

BBOT price history

1M range · 20 trading sessions · Daily adjusted prices

BBOT closed at $5.52 after 20 trading sessions, down 40.20% for the selected period.

Last close
$5.52
Period change
-40.20%
Period low
$5.52
Period high
$9.60
Daily close
View OHLC price history
BBOT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$6.785$6.785$5.48$5.522.79M
Sep 9, 2026$8.86$8.86$6.295$6.7551.5M
Sep 8, 2026$8.88$9.05$8.775$8.86154.11K
Sep 4, 2026$8.80$9.06$8.65$8.98117.62K
Sep 3, 2026$8.93$9.0411$8.66$8.90139.21K
Sep 2, 2026$8.81$9.185$8.73$8.89238.88K
Sep 1, 2026$8.70$8.90$8.535$8.82146.13K
Aug 31, 2026$8.72$9.195$8.4101$8.80476.04K
Aug 28, 2026$9.16$9.16$8.69$8.74195.04K
Aug 27, 2026$9.19$9.315$9.06$9.18385.27K
Aug 26, 2026$9.36$9.47$9.04$9.26247.15K
Aug 25, 2026$9.24$9.4725$9.18$9.37197.97K
Aug 24, 2026$9.10$9.3575$8.80$9.14338.52K
Aug 21, 2026$9.19$9.4351$9.03$9.08171.57K
Aug 20, 2026$9.55$9.78$9.08$9.08203.26K
Aug 19, 2026$9.16$9.72$9.14$9.60414.32K
Aug 18, 2026$9.02$9.125$8.82$8.95446.87K
Aug 17, 2026$8.90$9.3999$8.90$9.04249.91K
Aug 14, 2026$9.22$9.49$8.80$9.06227.48K
Aug 13, 2026$9.48$9.61$9.20$9.23303.83K

Latest BBOT news

The latest Smart Investors Daily articles mentioning BBOT.

Stock researchCompany · Overview

BBOT research

Overview

Company profile and research snapshot.

Company profile

BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$23.20
Implied upside
—
Analysts
—
BBOT recent ratings
DateFirmRatingTarget
Sep 9, 2026WedbushOutperform—
Aug 14, 2026JP MorganOverweight—
Jul 8, 2026JP MorganOverweight—
May 11, 2026Canaccord GenuityBuy—
Mar 6, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

Generated Sep 11, 2026, 3:08 PM

Why Is BBOT Down Today?

BridgeBio Oncology shares declined 6.14% today despite announcing new clinical data and strategic prioritization updates for its pipeline. The market's negative reaction suggests investor concerns may outweigh the positive developments from the company's oncology programs.

    Bottom line: Today's decline appears driven by investor disappointment that strategic announcements lacked specific clinical efficacy data to validate the company's pipeline positioning. While BridgeBio's focus on KRAS-mutant cancers and combination therapies represents rational scientific strategy, the market is signaling it needs concrete clinical evidence—not just strategic pivots—to support the stock valuation. Investors should monitor upcoming detailed data presentations and efficacy readouts as key catalysts.

    Yahoo · Sep 8, 2026

    BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers

    BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patientsBBO-8520 monotherapy continues to show highly competitive ORR in the 2L+ KRASG12C inhibitor-naïve NSCLC with ORR of 63% (26/41), disease control rate (DCR) of 100% (41/41) and no grade 3 liver enzyme elevationsBBO-11818 and BBO-10203 combination cohorts enrolling in KRAS-mutant CRC and PDAC$344.1 million in cash, cash equivalents and marketable securi

    Yahoo · Sep 1, 2026

    BBOT to Participate in Upcoming Investor Healthcare Conferences

    SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in upcoming investor conferences. Details of the company’s participation are as follows: Cantor Global Healthcare Conference 2026Wednesday, September 9, 2026, at 9:45 a.m. ET Citi's 2026 Biopharma Back to School ConferenceTh

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By